Reading view
Reply to: Utilizing foundation models for developing clinical tools
npj Digital Medicine, Published online: 18 November 2025; doi:10.1038/s41746-025-02066-3
Reply to: Utilizing foundation models for developing clinical toolsLarge language models driven neural architecture search for universal and lightweight disease diagnosis on histopathology slide images
npj Digital Medicine, Published online: 18 November 2025; doi:10.1038/s41746-025-02042-x
Large language models driven neural architecture search for universal and lightweight disease diagnosis on histopathology slide imagesCLINB: A Climate Intelligence Benchmark for Foundational Models
End to End AI System for Surgical Gesture Sequence Recognition and Clinical Outcome Prediction
UpBench: A Dynamically Evolving Real-World Labor-Market Agentic Benchmark Framework Built for Human-Centric AI
Learning to Trust: Bayesian Adaptation to Varying Suggester Reliability in Sequential Decision Making
Multi-agent Self-triage System with Medical Flowcharts
MiniGPT-Pancreas: Multimodal Large Language Model for Pancreas Cancer Classification and Detection
MedFedPure: A Medical Federated Framework with MAE-based Detection and Diffusion Purification for Inference-Time Attacks
Speculative Decoding in Decentralized LLM Inference: Turning Communication Latency into Computation Throughput
Uncertainty Makes It Stable: Curiosity-Driven Quantized Mixture-of-Experts
Real-Time Speech Enhancement via a Hybrid ViT: A Dual-Input Acoustic-Image Feature Fusion
Securing Generative AI in Healthcare: A Zero-Trust Architecture Powered by Confidential Computing on Google Cloud
EgoEMS: A High-Fidelity Multimodal Egocentric Dataset for Cognitive Assistance in Emergency Medical Services
A Workflow for Full Traceability of AI Decisions
A large language model-based approach to quantifying the effects of social determinants in liver transplant decisions
npj Digital Medicine, Published online: 17 November 2025; doi:10.1038/s41746-025-02025-y
A large language model-based approach to quantifying the effects of social determinants in liver transplant decisionsMethods for Analytical Validation of Novel Digital Clinical Measures: Implementation Feasibility Evaluation Using Real-World Datasets
The gut microbiome and gastrointestinal cancers: mechanisms, biomarkers and therapeutic opportunities
Front Physiol. 2025 Oct 30;16:1676796. doi: 10.3389/fphys.2025.1676796. eCollection 2025.
ABSTRACT
Gastrointestinal (GI) cancers remain a leading global cause of cancer-related mortality, significantly impacting public health and healthcare systems worldwide. Emerging evidence underscores the critical role of gut microbiome dysbiosis-characterized by disrupted microbial diversity and function-in GI carcinogenesis. Utilizing recent advancements in multi-omics technologies and sophisticated computational biology, researchers have elucidated distinct microbial signatures associated with colorectal, gastric, hepatobiliary, pancreatic, and esophageal cancers. This review comprehensively analyzes the primary mechanisms through which gut microbes contribute to cancer development and progression, encompassing genotoxicity, chronic inflammation, metabolic dysregulation, epigenetic modifications, and immunomodulation. Moreover, we explore innovative microbiome-derived biomarkers for potential clinical applications, including early diagnosis, prognosis assessment, and therapeutic response prediction. The intricate interactions between microbiota and standard cancer therapies-chemotherapy, immunotherapy, and radiation therapy-are discussed, highlighting microbiome influences on therapeutic efficacy and adverse effect profiles. We also critically assess the impact of modifiable factors such as diet, medications, lifestyle, and environmental exposures on microbiome composition and cancer risk. The review evaluates emerging therapeutic interventions, including dietary modifications, probiotics, prebiotics, fecal microbiota transplantation (FMT), and engineered live biotherapeutics. Despite notable advancements, significant hurdles remain, including clarifying causality, methodological standardization, and equitable global research representation. Addressing these challenges, we propose a strategic research agenda aimed at harnessing microbiome insights to advance precision oncology and improve GI cancer outcomes globally.
PMID:41245267 | PMC:PMC12611654 | DOI:10.3389/fphys.2025.1676796
The gut microbiome and gastrointestinal cancers: mechanisms, biomarkers and therapeutic opportunities
Front Physiol. 2025 Oct 30;16:1676796. doi: 10.3389/fphys.2025.1676796. eCollection 2025.
ABSTRACT
Gastrointestinal (GI) cancers remain a leading global cause of cancer-related mortality, significantly impacting public health and healthcare systems worldwide. Emerging evidence underscores the critical role of gut microbiome dysbiosis-characterized by disrupted microbial diversity and function-in GI carcinogenesis. Utilizing recent advancements in multi-omics technologies and sophisticated computational biology, researchers have elucidated distinct microbial signatures associated with colorectal, gastric, hepatobiliary, pancreatic, and esophageal cancers. This review comprehensively analyzes the primary mechanisms through which gut microbes contribute to cancer development and progression, encompassing genotoxicity, chronic inflammation, metabolic dysregulation, epigenetic modifications, and immunomodulation. Moreover, we explore innovative microbiome-derived biomarkers for potential clinical applications, including early diagnosis, prognosis assessment, and therapeutic response prediction. The intricate interactions between microbiota and standard cancer therapies-chemotherapy, immunotherapy, and radiation therapy-are discussed, highlighting microbiome influences on therapeutic efficacy and adverse effect profiles. We also critically assess the impact of modifiable factors such as diet, medications, lifestyle, and environmental exposures on microbiome composition and cancer risk. The review evaluates emerging therapeutic interventions, including dietary modifications, probiotics, prebiotics, fecal microbiota transplantation (FMT), and engineered live biotherapeutics. Despite notable advancements, significant hurdles remain, including clarifying causality, methodological standardization, and equitable global research representation. Addressing these challenges, we propose a strategic research agenda aimed at harnessing microbiome insights to advance precision oncology and improve GI cancer outcomes globally.
PMID:41245267 | PMC:PMC12611654 | DOI:10.3389/fphys.2025.1676796